Acumen Research and Consulting estimates that global bio banking market is expected to reach the market value of around US$ 70 Bn by 2027 and is anticipated to grow at a CAGR of around 5% in terms of revenue amid the forecast period 2020 – 2027.
The report provides analysis of global bio banking market for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.
Market Insights
Cord blood cells from premature infants are being rapidly retained. The blood cord works to treat any problems that can develop at any age for the infant. It is rich in hematopoietic stem cells that can both distinguish themselves into myeloid and lymphoid cell lines and have the properties of self-renovation. This also continues to heal infections, wounds and injuries at all levels of life. As a result, the biobanks that hold cord blood cells prosper at a rapid rate in different areas, with an increasing understanding of the advantages of holding umbilical cables that ultimately contribute to the worldwide development of biobank industry.
In addition, there is a growing demand for cord blood and stem cells globally as these therapies can assist in tissue graft, organ transplantation, regenerative medicine and drug testing, and the increasing prevalence of chronic diseases such as Alzheimer, Parkinson's disease and diabetes, results in an increase in biobank demand, which boosts market growth.
Moreover, increased funding has been provided for biobanks for the preservation, analytics, transportation and collection of samples in increased research activities focusing on the unmet needs of various chronic diseases, such as diabetes, ischemic hearts, cancer, respiratory disorders. For example, in May 2017 the German Federal Ministry of Education and Research (BMBF) received US $16 Mn from 11 German biobanks. Therefore, the biobank industry is expected to expand in the coming years, with growing funds being made available to biobanks.
High chronic conditions incidence
Several medical diseases such as psychiatric, neurological and immunological disorders cannot be treated using traditional treatments because they have negative side effects. By integrating it with stem cell therapy, which works to reduce the damage due to doses of treatments, the risk of these side effects could be reduced. Moreover, about 14.5 Mn people suffer from cancer in the US, and this is expected to rise to 19 Mn by 2024, according to estimates from the National Cancer Institute. The cord blood needs for therapeutic purposes are projected to increase and thereby drive development on the global biobanking industry.
Regional Stance
North America has substantial share of the global demand in biobanks and, without major variations, will show a consistent pattern over the projected period. The US is having the biggest R&D and improved health infrastructure expenditure in the world. The biobanking storages of RNA, DNA, tissue, blood, plasma, serum, cells, etc. are being used by a number of pharmaceutical/biotech companies, academia and institutions. Therefore, the region is projected to see high market share in the future with rising R&D investment and expanding healthcare facilities.
Due to the availability of well-established networks and facilities for biospecimen collection, storage and recovery, European countries made a major contribution in 2019. EuroBioBank and BBMRI – ERIC are two major Europe-wide biobanking networks that finance healthcare and science in the area. A large number of new biospecimens are deposited in Asia Pacific, which will be the most steadily increasing over the forecast period.
Key Players & Strategies
Participants include major global players Worthington Industries, Tecan Trading AG, Thermo Fisher Scientific Inc, QIAGEN, TTP Labtech, Brooks Life Sciences, VWR International, LLC, Promega Corporation, BD, Hamilton Company, Biokryo GmbH, Merck KGaA, and Others.
Most biobanks are created in order to satisfy the resource-related needs of bigger businesses. In the coming years, an increasing number of competitive biorepositories would improve demand. In addition, leading players like Thermo Fisher and Lonza have increased their position in the industry by expanding their portfolio to biobanking facilities like sample collection, storage, analysis and transport.
Market Segmentation
Biobanking Market by Specimen
Blood products
Cell lines
Solid tissue
Others
Biobanking Market by Application
Research
Therapeutic
Biobanking Market by Type
Disease-oriented biobanks
Population-based biobanks
Biobanking Market by Ownership
National/regional agencies
University
Nonprofit organization
Private
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Biobanking
1.1. Definition and Scope
1.1.1. Definition of Biobanking
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Biobanking Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Biobanking Market By Specimen
1.2.3. Biobanking Market By Type
1.2.4. Biobanking Market By Ownership
1.2.5. Biobanking Market By Application
1.2.6. Biobanking Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Biobanking Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Value Chain Analysis
3.6.1. List of Key Manufacturers
3.6.2. List of Customers
3.6.3. Level of Integration
3.7. Regulatory Compliance
3.8. Competitive Landscape, 2019
3.8.1. Player Positioning Analysis
3.8.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Biobanking Market By Specimen
4.1. Introduction
4.2. Biobanking Revenue By Specimen
4.2.1. Biobanking Revenue (US$ Mn) and Forecast, By Specimen, 2016-2027
4.2.2. Blood products
4.2.2.1. Blood products Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.3. Cell Lines
4.2.3.1. Cell Lines Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.4. Solid Tissues
4.2.4.1. Solid Tissues Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.5. Others
4.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 5. Biobanking Market Revenue By Type
5.1. Introduction
5.2. Biobanking Revenue (US$ Mn) By Type
5.2.1. Biobanking Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
5.2.2. Disease-oriented biobanks
5.2.2.1. Disease-oriented biobanks Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Population-based biobanks
5.2.3.1. Population-based biobanks Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Biobanking Market By Ownership
6.1. Introduction
6.2. Biobanking Revenue (US$ Mn) By Ownership
6.2.1. Biobanking Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
6.2.2. National/regional agencies
6.2.2.1. National/regional agencies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. University
6.2.3.1. University
6.2.4. Nonprofit organization
6.2.4.1. Ultraviolet-visible spectroscopy Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Private
6.2.5.1. Private Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Biobanking Market By Application
7.1. Introduction
7.2. Biobanking Revenue (US$) By Application
7.2.1. Biobanking Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.3. Research
7.3.1. Research Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.4. Therapeutic
7.4.1. Therapeutic Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Biobanking Market By Country
8.1. North America Biobanking Overview
8.2. U.S.
8.2.1. U.S. Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
8.2.2. U.S. Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.3. U.S. Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
8.2.4. U.S. Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.3. Canada
8.3.1. Canada Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
8.3.2. Canada Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.3. Canada Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
8.3.4. Canada Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Biobanking Market By Country
9.1. Europe Biobanking Market Overview
9.2. U.K.
9.2.1. U.K. Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
9.2.2. U.K. Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.2.3. U.K. Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
9.2.4. U.K. Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.3. Germany
9.3.1. Germany Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
9.3.2. Germany Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.3.3. Germany Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
9.3.4. Germany Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.4. France
9.4.1. France Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
9.4.2. France Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.4.3. France Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
9.4.4. France Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.5. Spain
9.5.1. Spain Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
9.5.2. Spain Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.5.3. Spain Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
9.5.4. Spain Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016-2027
9.6.2. Rest of Europe Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.6.3. Rest of Europe Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016-2027
9.6.4. Rest of Europe Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Biobanking Market By Country
10.1. Asia Pacific Biobanking Market Overview
10.2. China
10.2.1. China Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.2.2. China Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.3. China Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.2.4. China Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.3. Japan
10.3.1. Japan Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.3.2. Japan Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.3. Japan Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.3.4. Japan Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.4. India
10.4.1. India Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.4.2. India Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.4.3. India Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.4.4. India Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.5. Australia
10.5.1. Australia Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.5.2. Australia Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.5.3. Australia Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.5.4. Australia Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.6.2. South Korea Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.6.3. South Korea Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.6.4. South Korea Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
10.7.2. Rest of Asia-Pacific Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.7.3. Rest of Asia-Pacific Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
10.7.4. Rest of Asia-Pacific Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Biobanking Market By Country
11.1. Latin America Biobanking Market Overview
11.2. Brazil
11.2.1. Brazil Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
11.2.2. Brazil Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.2.3. Brazil Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
11.2.4. Brazil Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
11.3.2. Mexico Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.3.3. Mexico Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
11.3.4. Mexico Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
11.4.2. Rest of Latin America Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.4.3. Rest of Latin America Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
11.4.4. Rest of Latin America Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
CHAPTER 12. Middle East & Africa Biobanking Market By Country
12.1. Middle East & Africa Biobanking Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
12.2.2. Saudi Arabia Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.2.3. Saudi Arabia Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
12.2.4. Saudi Arabia Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.3. UAE
12.3.1. UAE Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
12.3.2. UAE Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.3.3. UAE Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
12.3.4. UAE Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Biobanking Market Revenue (US$ Mn) and Forecast By Specimen, 2016 - 2027
12.4.2. Rest of Middle East & Africa Biobanking Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.4.3. Rest of Middle East & Africa Biobanking Market Revenue (US$ Mn) and Forecast By Ownership, 2016 - 2027
12.4.4. Rest of Middle East & Africa Biobanking Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
CHAPTER 13. PLAYER ANALYSIS OF Biobanking
13.1. Biobanking Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Biobanking Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. Worthington Industries
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. Worthington Industries 2019 Biobanking Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. Tecan Trading AG
14.3. Thermo Fisher Scientific Inc
14.4. QIAGEN
14.5. TTP Labtech
14.6. Brooks Life Sciences
14.7. VWR International LLC
14.8. Promega Corporation
14.9. BD
14.10. Hamilton Company.
14.11. Biokryo GmbH
14.12. Merck KGaA
14.13. Others
